CAS: 16034-46-1; 1-Methyl-1H-Pyrazole-5-Carboxylic Acid

上下游产品

CAS号930-36-9 1-甲基吡唑 | CAS号124-38-9 二氧化碳 | CAS号1621-91-6 吡唑-3-羧酸 | CAS号77-78-1 硫酸二甲酯 | CAS号201230-82-2 carbon monoxide | CAS号694-31-5 1,5-二甲基-1H-吡唑 | CAS号27258-33-9 1-甲基-1H-吡唑-5-甲醛 | CAS号109-72-8 正丁基锂 | CAS号60-29-7 乙醚 | CAS号591-51-5 苯基锂 | CAS号92534-69-5 1-甲基-4-硝基-1H-吡唑-5-羧酸 | CAS号92534-73-1 4-氨基-1-甲基-1H-吡唑... | CAS号84547-61-5 5-羟甲基-1-甲基-1H-吡唑 | CAS号84547-84-2 4-溴-2-甲基-2H-吡唑-3-羧酸 | CAS号84547-59-1 1-甲基-1H-吡唑-5-羰酰氯 | CAS号84547-83-1 4-氯-1-甲基-1H-吡唑-5-羧酸 | CAS号930-36-9 1-甲基吡唑 | CAS号75092-30-7 4-碘-1-甲基-1H-吡唑-5-羧酸 | CAS号137890-05-2 1-甲基-5-乙酰基吡唑 | CAS号17827-60-0 1-甲基-1H-吡唑-5-甲酸甲酯

2-(1-甲基-1H-吡唑-5-基)乙醇置于potassium Permanganate,Potassium Carbonate体系中,用 水 用作溶剂,化学反应 4.0H,以64%的收率获得1-甲基-1H-吡唑-5-羧酸
参考文献:所有异构的2-(吡唑基)乙醇的合成和氧化
标题:所有异构的2-(吡唑基)乙醇的合成和氧化
摘要:描述了一种基于3-(二甲氧基甲基)-2-甲氧基四氢呋喃与肼的再循环反应制备n-取代的2-(吡唑-4-基)乙醇的有效方法.用kmno 4氧化产生2-(吡唑-4-基)-2-氧乙酸.相反,在类似条件下的2-(吡唑-5-基)乙醇仅产生吡唑-5-羧酸,其是通过氧化然后脱羰而形成的.在该氧化反应中的2-(吡唑-3-基)乙醇得到2-氧代-2-(吡唑-3-基)乙酸和吡唑-3-羧酸的混合物.
Doi:10.1007/s10593-020-02662-Z

专利信息

专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-2010160351-A1
优先权日:2008-12-19
标题:Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
发明人：JENKINS HELEN; KITT MICHAEL; PEARLMAN RODNEY; SERAFINI TITO; THORSETT EUGENE
权利人:NUON THERAPEUTICS INC
摘要:Disclosed is a pharmaceutical composition comprising (a) a first therapeutic agent, wherein the first therapeutic agent is a compound of formula II: n n n n n n n n n n n n or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein; (b) a second therapeutic agent, wherein the second therapeutic agent is a uric acid synthesis inhibitor or a uricosuric agent; and (c) a pharmaceutically acceptable diluent or carrier.

专利号:US-4317823-A
优先权日:1979-08-03
标题 :Pyrazolobenzodiazepinones, their intermediates, their compositions and their use
发明人：RAINER GEORG
权利人:BYK GULDEN LOMBERG CHEM FAB
摘要:1-(Lower)alkyl-4-(substituted)aminoalkylcarbonyl-1,4,9,10-tetrahydropy razolo[4,3-b][1,5]benzodiazepin-10-ones are useful, e.g., to protect warm blooded animals against the formation of gastric ulcers. They are active ingredients in otherwise conventional medicament compositions administered enterally or parenterally in standard dosage forms. Their synthesis, their novel intermediates and their acid-addition salts are described.